Business
Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan
SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development
About this update from Ainos, Inc.
[{"type":"text","content":"SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ainos, Inc. (OTC PINK:AIMD) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that the Company has begun marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test (\"COVID-19 Antigen Self-Test Kit\" or \"the Test\") under an Emergency Use Authorization (\"EUA\") issued by the Taiwan Food and Drug Administration (\"TFDA\") on June 13, 2022 to Taiwan Carbon Nano Technology Corporation (\"TCNT\"), the manufacturer and product co-developer of the Test in conjunction with Ainos. Ainos is the exclusive master sales and marketing agent for the COVID-19 Antigen Self-Test Kit.The Company has been marketing the Ainos COVID-19 Rapid Test Kit for use by healthcare professionals in Taiwan under an EUA issued by the TFDA to TCNT since June 2021. Building on the diagnostics technology of its professional-use test kits, the Ainos COVID-19 Antigen Self-Test Kit is for at-home use and intended for the qualitative detection of SARS-CoV-2 virus from direct nasal swab specimens collected by individual users. The Test is designed to detect whether SARS-CoV-2, including the Omicron variant, is present in a sample and deliver results in as little as 15 minutes.Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, \"The growth in COVID-19 cases from the Omicron variant has significantly increased demand for at-home testing in Taiwan. Making accurate and rapid diagnostic tools such as the Ainos COVID-19 Antigen Self-Test Kit available for use by both individuals and healthcare professionals is vital for the detection and control of COVID-19.\"About Ainos, Inc.Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of med...